9.21.26
The biotechnology, pharmaceuticals and genetics industry is entering one of the most consequential periods in its history. Artificial intelligence, gene editing, dramatically cheaper DNA sequencing, personalized medicine, new cancer treatments and a booming market for obesity drugs are changing both the science and economics of medicine. At the same time, drug companies face intense pressure from soaring research costs, patent expirations, biosimilar competition and government efforts to restrain prices.
Even more information on this industry is available! Check out our Biotech Industry Center.
Plunkett’s Biotech, Pharmaceuticals & Genetics Industry eBook, latest edition.
1. The rapid integration of artificial intelligence into pharmaceutical research and development.
Drug companies are using AI for target identification, molecular design, protein analysis, clinical-trial optimization and patient selection. AI systems can analyze enormous quantities of biological and chemical data and run simulations continuously, potentially reducing the time and expense involved in finding promising new compounds. The technology is also being used to identify new uses for medicines that have already received regulatory approval. AI is therefore shifting from an experimental tool into a core part of pharmaceutical R&D.
2. The extraordinary growth of GLP-1 obesity and diabetes treatments
Novo Nordisk’s Wegovy and Ozempic and Eli Lilly’s Zepbound helped demonstrate that drugs acting on GLP-1 pathways could produce major weight loss while also treating diabetes. Researchers are now exploring potential benefits involving cardiovascular, kidney and liver disease, sleep apnea, Alzheimer’s disease and even alcohol or drug addiction.
The market is also becoming more competitive and convenient. Newer oral alternatives reduce the need for injections, while expanded manufacturing capacity and competition are putting downward pressure on prices. The report notes that the global market opportunity remains immense and that these treatments could rank among the highest-grossing pharmaceuticals in history.
3. Genetics and personalized medicine evolve.
The cost of sequencing a nearly complete human genome has fallen from roughly $100 million in 2001 to about $100 to $200 today. That extraordinary decline makes it increasingly practical to analyze patients’ genetic profiles and select drugs based on how an individual is likely to respond. Genetic information may also help physicians determine appropriate dosages and identify mutations that are driving disease.
4. Gene therapy and CRISPR gene editing make great strides.
Gene therapies attempt to correct defective genes or introduce functioning copies, potentially attacking the underlying cause of an illness rather than simply treating symptoms. CRISPR provides scientists with an increasingly precise way to edit specific portions of DNA. Research is also moving toward in vivo treatments that edit genes directly inside the body.
Perhaps even more significant commercially, genetic medicine may eventually move beyond extremely rare diseases. Researchers are exploring epigenetic approaches that alter gene activity without permanently cutting DNA, including therapies aimed at cardiovascular disease. If successful, genetic medicines could address much larger patient populations and become a major part of mainstream medicine.
5. mRNA technology is moving beyond its pandemic-era role.
COVID-19 vaccines demonstrated that mRNA platforms could be designed and produced rapidly. Pharmaceutical developers are now applying the technology to cancer and personalized medicine. The report highlights 2026 Phase 3 results from Moderna and Merck involving an individualized mRNA treatment combined with Keytruda for advanced melanoma. Tumor material is sequenced and used to create a customized vaccine that teaches the patient’s immune system to recognize specific cancer cells.
6. Cancer treatment becomes more targeted and personalized.
Immunotherapies encourage the immune system to attack malignant cells, while CAR-T therapies re-engineer a patient’s white blood cells. Antibody-drug conjugates deliver cancer-killing agents more directly to tumors. Genetic sequencing is simultaneously helping physicians determine which therapies are likely to work for particular patients. These techniques represent a fundamental shift away from treating cancers solely according to where they originate in the body and toward treating them according to their underlying biological and genetic characteristics.
7. Large pharmaceutical companies increasingly rely on smaller biotech firms for innovation.
Patent expirations threaten established blockbusters, encouraging large firms to acquire, license or partner with companies that possess promising drug pipelines. Rather than relying only on gigantic corporate mergers, pharmaceutical companies are increasingly making smaller acquisitions and licensing deals that spread risk across multiple technologies and drug candidates.
8. China emerges as a major source of new drugs rather than merely a manufacturing base or sales market.
Western and Japanese pharmaceutical companies entered 70 deals with Chinese biotech firms during 2025, paying a cumulative $5.6 billion for rights to promising molecules. Major 2026 agreements included AstraZeneca’s deal with CSPC Pharmaceutical and Bristol Myers Squibb’s partnership with Hengrui Pharma.
9. Innovation is extremely expensive while governments and consumers increasingly demand lower drug prices.
U.S. prescription-drug spending was forecast at $561.5 billion in 2026, while Plunkett Research estimated the global pharmaceuticals market at roughly $1.9 trillion. Drug development can require investments approaching or exceeding $1 billion per successful therapy, while many experimental compounds never reach the market.
Pressure will intensify as major patents expire, biosimilars become more common and Medicare exercises new drug-price negotiating powers. Generics already represented about 90% of U.S. prescriptions by volume in 2025, while major products such as Keytruda face eventual patent expiration.
10. The future.
Taken together, these developments point toward an industry that is becoming increasingly AI-enabled, genetically targeted, personalized, global and partnership-driven. The scientific opportunities are extraordinary, but so are the financial and regulatory challenges. Companies that can combine breakthrough biology with efficient development, scalable manufacturing and sustainable pricing are likely to shape the next era of medicine.
Key Concepts: Biotechnology, business, genetics, economics, genomics, entrepreneurship, finance, science, globalization, healthcare, innovation, investing, marketing, artificial intelligence (AI), CRISPR, mRNA
Source: Plunkett Research, Ltd., Copyright © 2026
